ENSA: A Potential Drug Target for Neurological Disorders (G2029)

Target Name: ENSA

NCBI ID: G2029

ENSA

ENSA: A Potential Drug Target for Neurological Disorders

ENSA (ENSA variant 3) is a protein that is expressed in the nervous system and has been identified as a potential drug target for various neurological and psychiatric disorders. ENSA is a key regulator of the nervous system and is involved in the development and maintenance of neuronal excitability. ENSA variants have been shown to be associated with a number of neurological and psychiatric disorders, including autism, schizophrenia, and depression.

One of the key features of ENSA is its role in modulating the strength of neural synapses. Neural synapses are the connections between neurons, and the strength of these connections is critical for the proper functioning of the nervous system. ENSA is involved in regulating the amount of a protein called synaptophysin, which is involved in the formation and maintenance of synapses.

Research has also shown that ENSA is involved in the regulation of neurotransmitter release from neurons. Neuronal communications are critical for the proper functioning of the nervous system, and ENSA plays a key role in regulating the release of neurotransmitters such as dopamine, serotonin, and GABA.

In addition to its role in modulating neural synapses and neurotransmitter release, ENSA is also involved in the regulation of neuronal growth and differentiation. Neurons are generated during development and must be properly regulated in order to function properly. ENSA is involved in the regulation of cell survival and proliferation, as well as the proper formation of neuronal connections.

The potential drug targets for ENSA are vast, and include a number of different neurological and psychiatric disorders. Given its role in the regulation of neural synapses, ENSA may be a good candidate for treatments related to neurotransmission, such as antidepressants or antipsychotics. ENSA may also be a good candidate for treatments related to neuroplasticity, such as brain training or cognitive stimulation.

In addition to its potential therapeutic applications, ENSA is also an interesting biomarker for a number of neurological and psychiatric disorders. The regulation of neural synapses and neurotransmission is often impaired in these disorders, and ENSA may be a useful indicator of the severity and progression of these disorders. For example, ENSA levels have been shown to be elevated in individuals with autism, and may be a potential biomarker for this disorder.

Overall, ENSA is a protein that is expressed in the nervous system and has a number of potential therapeutic applications. Its role in the regulation of neural synapses and neurotransmission, as well as its involvement in the regulation of neuronal growth and differentiation, make it an attractive candidate for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the potential of ENSA as a drug target and biomarker.

Protein Name: Endosulfine Alpha

Functions: Protein phosphatase inhibitor that specifically inhibits protein phosphatase 2A (PP2A) during mitosis. When phosphorylated at Ser-67 during mitosis, specifically interacts with PPP2R2D (PR55-delta) and inhibits its activity, leading to inactivation of PP2A, an essential condition to keep cyclin-B1-CDK1 activity high during M phase (By similarity). Also acts as a stimulator of insulin secretion by interacting with sulfonylurea receptor (ABCC8), thereby preventing sulfonylurea from binding to its receptor and reducing K(ATP) channel currents

The "ENSA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENSA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets